[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fqqvzyYnQVwP-HHrwJT1izCpY3dzbr9-Px0Sp60i9lTY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Biocad",[4],93,false,25,45,14470,49,0,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Healthy",12,{"name":18,"count":19},"Melanoma",7,{"name":21,"count":22},"Multiple Sclerosis",5,{"name":24,"count":22},"Rheumatoid Arthritis",{"name":26,"count":27},"Ankylosing Spondylitis",4,{"name":29,"count":27},"Melanoma (Skin)",{"name":31,"count":32},"Anemia",3,{"name":34,"count":32},"Hepatitis",[36,41,46,51,56,61,66,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06112808","A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","2024-01-31","BCD-263",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05732805","A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable\u002FMetastatic Melanoma","2024-06-20","BCD-217",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05800327","A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis","2024-09","Levilimab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05726630","Clinical Study of Divozilimab in Patients With Systemic Scleroderma","2024-10-01","Divozilimab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06333210","Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)","2024-12","anti-TRBV9 monoclonal antibody infusions",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05730699","Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)","2025-01","divozilimab",{"nctId":67,"briefTitle":68,"date":64,"intervention":69},"NCT06296121","A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma","BCD-264",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06715540","Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects","2025-02","BCD-261, dose 1",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05802225","Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","2025-06-06","BCD-178",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05747261","Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)","2025-09","ANB-004, dose 1",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,149,198,230,252,343,393,415,447,469,505,537,569,591,609,631,649,675,700,718,736,773,795,817,841,859,886,904,922,949,967,985,1010,1028,1053,1077,1095,1113,1131,1158,1176,1194,1212,1230,1248,1266,1284,1310,1328,1346,1410,1460,1497,1544,1570,1605,1635,1669,1708,1745,1781,1815,1851,1873,1895,1932,1954,1992,2018,2040,2058,2076,2102,2120,2147,2165,2193,2211,2229,2254,2272,2290,2308,2326,2351,2369,2387,2405,2423,2441,2465,2487,2505,2523,2541,2566,2584,2602,2620,2638,2656,2682,2700,2727,2750,2768,2786,2804,2822,2845,2869,2899,2917,2935,2953,2971,2989,3007,3030,3051,3074,3097,3122,3140,3163,3188,3206],{"intervention":55,"totalTrials":27,"cells":94},{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":113,"PHASE3":115,"PHASE4":145,"NA":147},{"trials":96,"activeCount":12},[],{"trials":98,"activeCount":112,"soonestReadout":104},[99],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT07136389","Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus","RECRUITING",[87],"2026-01-01","2026-11-01","2025-03-27",135,[109],"Systemic Lupus Erthematosus",[111,111,111,55,111],"BCD-256",1,{"trials":114,"activeCount":12},[],{"trials":116,"activeCount":144,"soonestReadout":54},[117,126,134],{"nctId":62,"briefTitle":63,"status":118,"phases":119,"primaryCompletion":64,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"ACTIVE_NOT_RECRUITING",[89],"2026-09","2022-12-12",105,[124],"Neuromyelitis Optica Spectrum Disorders",[65],{"nctId":52,"briefTitle":53,"status":118,"phases":127,"primaryCompletion":54,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},[89],"2027-02-01","2022-12-26",152,[132],"Systemic Scleroderma",[55],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":143},"NCT06987851","An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD","COMPLETED",[89],"2024-05-16","2022-03-22",44,[21],[55],2,{"trials":146,"activeCount":12},[],{"trials":148,"activeCount":12},[],{"intervention":45,"totalTrials":32,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":170,"PHASE4":194,"NA":196},{"trials":152,"activeCount":12},[],{"trials":154,"activeCount":12},[],{"trials":156,"activeCount":12},[157],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT03913923","Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma","UNKNOWN",[88],"2023-07","2023-12","2019-07-01",117,[18,167],"Melanoma Metastatic",[45,169],"BCD-100",{"trials":171,"activeCount":144,"soonestReadout":44},[172,184],{"nctId":173,"briefTitle":174,"status":118,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT05751928","A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma",[89],"2027-01","2027-06","2023-04-05",411,[181,29],"Melanoma Stage III",[45,183],"anti-PD1",{"nctId":42,"briefTitle":43,"status":118,"phases":185,"primaryCompletion":44,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":193},[89],"2025-07","2022-08-02",270,[18,29,181,190,191,167,192],"Melanoma Stage IV","Melanoma Unresectable","Melanoma Advanced",[45,169],{"trials":195,"activeCount":12},[],{"trials":197,"activeCount":12},[],{"intervention":40,"totalTrials":144,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":212,"PHASE3":214,"PHASE4":226,"NA":228},{"trials":201,"activeCount":12},[],{"trials":203,"activeCount":112,"soonestReadout":39},[204],{"nctId":37,"briefTitle":38,"status":118,"phases":205,"primaryCompletion":39,"completion":176,"start":206,"enrollment":207,"conditions":208,"interventions":210},[87],"2023-05-29",300,[209],"Advanced Melanoma",[40,211],"Opdivo",{"trials":213,"activeCount":12},[],{"trials":215,"activeCount":112,"soonestReadout":220},[216],{"nctId":217,"briefTitle":218,"status":118,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":225},"NCT06640530","Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin",[89],"2025-12","2027-03","2024-03-21",392,[209,29],[40,211],{"trials":227,"activeCount":12},[],{"trials":229,"activeCount":12},[],{"intervention":211,"totalTrials":144,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":240,"PHASE3":242,"PHASE4":248,"NA":250},{"trials":233,"activeCount":12},[],{"trials":235,"activeCount":112,"soonestReadout":39},[236],{"nctId":37,"briefTitle":38,"status":118,"phases":237,"primaryCompletion":39,"completion":176,"start":206,"enrollment":207,"conditions":238,"interventions":239},[87],[209],[40,211],{"trials":241,"activeCount":12},[],{"trials":243,"activeCount":112,"soonestReadout":220},[244],{"nctId":217,"briefTitle":218,"status":118,"phases":245,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":246,"interventions":247},[89],[209,29],[40,211],{"trials":249,"activeCount":12},[],{"trials":251,"activeCount":12},[],{"intervention":169,"totalTrials":253,"cells":254},8,{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":271,"PHASE3":301,"PHASE4":339,"NA":341},{"trials":256,"activeCount":12},[],{"trials":258,"activeCount":12},[259],{"nctId":260,"briefTitle":261,"status":160,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":270},"NCT03050047","A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors",[87],"2017-07-01","2018-11","2016-08-30",15,[18,268,269],"Lung Cancer","Renal Cell Carcinoma",[169],{"trials":272,"activeCount":12},[273,277,291],{"nctId":158,"briefTitle":159,"status":160,"phases":274,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":275,"interventions":276},[88],[18,167],[45,169],{"nctId":278,"briefTitle":279,"status":160,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":11,"conditions":283,"interventions":287},"NCT03912402","Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)",[88],"2020-07-07","2018-12-25",[284,285,286],"Cervical Cancer","Cervical Cancer Metastatic","Cervical Cancer Recurrent",[169,288,289,290],"Bevacizumab","Paclitaxel","Cisplatin",{"nctId":292,"briefTitle":293,"status":160,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":300},"NCT03269565","International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma",[88],"2018-08-29","2021-01","2017-08-31",126,[18],[169],{"trials":302,"activeCount":112,"soonestReadout":44},[303,313,322,335],{"nctId":304,"briefTitle":305,"status":160,"phases":306,"primaryCompletion":163,"completion":163,"start":307,"enrollment":308,"conditions":309,"interventions":311},"NCT03912389","Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC",[89],"2019-06-01",292,[310],"Non-Squamous Non-Small Cell Neoplasm of Lung",[169,312,290],"Pemetrexed",{"nctId":314,"briefTitle":315,"status":160,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":321},"NCT03912415","Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)",[89],"2024-12-01","2019-10-01",316,[284],[169,288,289,290],{"nctId":323,"briefTitle":324,"status":160,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":333},"NCT03288870","Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)",[88,89],"2020-08-10","2021-08-10","2017-09-19",218,[331,332],"Non Small Cell Lung Cancer Stage IIIB","Non-Small Cell Carcinoma of Lung, TNM Stage 4",[169,334],"Docetaxel",{"nctId":42,"briefTitle":43,"status":118,"phases":336,"primaryCompletion":44,"completion":186,"start":187,"enrollment":188,"conditions":337,"interventions":338},[89],[18,29,181,190,191,167,192],[45,169],{"trials":340,"activeCount":12},[],{"trials":342,"activeCount":12},[],{"intervention":344,"totalTrials":32,"cells":345},"BCD-131",{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":361,"PHASE3":374,"PHASE4":389,"NA":391},{"trials":347,"activeCount":12},[],{"trials":349,"activeCount":12},[350],{"nctId":351,"briefTitle":352,"status":137,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":9,"conditions":356,"interventions":358},"NCT02731469","Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers",[87],"2017-03","2016-06-15",[357],"Reticulocyte Count",[344,359,360],"Mircera®","Aranesp®",{"trials":362,"activeCount":12},[363],{"nctId":364,"briefTitle":365,"status":137,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT03519243","Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis",[88],"2018-12-01","2018-12-10","2017-10-24",75,[31],[344,373],"Mircera",{"trials":375,"activeCount":112,"soonestReadout":380},[376],{"nctId":377,"briefTitle":378,"status":102,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":388},"NCT07119372","Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis",[89],"2026-05","2026-11","2025-03-01",228,[31,385,386,387],"Chronic Kidney Disease","Chronic Kidney Disease Patients on Hemodialysis","Chronic Kidney Disease 5D",[344,373],{"trials":390,"activeCount":12},[],{"trials":392,"activeCount":12},[],{"intervention":373,"totalTrials":144,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":405,"PHASE4":411,"NA":413},{"trials":396,"activeCount":12},[],{"trials":398,"activeCount":12},[],{"trials":400,"activeCount":12},[401],{"nctId":364,"briefTitle":365,"status":137,"phases":402,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":403,"interventions":404},[88],[31],[344,373],{"trials":406,"activeCount":112,"soonestReadout":380},[407],{"nctId":377,"briefTitle":378,"status":102,"phases":408,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":409,"interventions":410},[89],[31,385,386,387],[344,373],{"trials":412,"activeCount":12},[],{"trials":414,"activeCount":12},[],{"intervention":69,"totalTrials":144,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":431,"PHASE3":433,"PHASE4":443,"NA":445},{"trials":418,"activeCount":12},[],{"trials":420,"activeCount":12},[421],{"nctId":422,"briefTitle":423,"status":137,"phases":424,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":429},"NCT05974969","A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects",[87],"2023-08-15","2023-05-17",146,[15],[69,430],"Darzalex",{"trials":432,"activeCount":12},[],{"trials":434,"activeCount":112,"soonestReadout":64},[435],{"nctId":67,"briefTitle":68,"status":102,"phases":436,"primaryCompletion":64,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},[89],"2026-07","2023-12-21",252,[441],"Multiple Myeloma",[69,430],{"trials":444,"activeCount":12},[],{"trials":446,"activeCount":12},[],{"intervention":430,"totalTrials":144,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":457,"PHASE3":459,"PHASE4":465,"NA":467},{"trials":450,"activeCount":12},[],{"trials":452,"activeCount":12},[453],{"nctId":422,"briefTitle":423,"status":137,"phases":454,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":455,"interventions":456},[87],[15],[69,430],{"trials":458,"activeCount":12},[],{"trials":460,"activeCount":112,"soonestReadout":64},[461],{"nctId":67,"briefTitle":68,"status":102,"phases":462,"primaryCompletion":64,"completion":437,"start":438,"enrollment":439,"conditions":463,"interventions":464},[89],[441],[69,430],{"trials":466,"activeCount":12},[],{"trials":468,"activeCount":12},[],{"intervention":470,"totalTrials":144,"cells":471},"Adalimumab",{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":485,"PHASE3":487,"PHASE4":501,"NA":503},{"trials":473,"activeCount":12},[],{"trials":475,"activeCount":12},[476],{"nctId":477,"briefTitle":478,"status":137,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT02395055","Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers",[87],"2015-10","2015-06",94,[15],[470,470],{"trials":486,"activeCount":12},[],{"trials":488,"activeCount":112,"soonestReadout":493},[489],{"nctId":490,"briefTitle":491,"status":118,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":499},"NCT06640517","Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis",[89],"2026-06","2028-02","2024-08-08",140,[498],"Plaque Psoriasis",[500,470],"Netakimab",{"trials":502,"activeCount":12},[],{"trials":504,"activeCount":12},[],{"intervention":50,"totalTrials":144,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":533,"NA":535},{"trials":508,"activeCount":12},[],{"trials":510,"activeCount":12},[],{"trials":512,"activeCount":12},[],{"trials":514,"activeCount":112,"soonestReadout":49},[515,522],{"nctId":47,"briefTitle":48,"status":118,"phases":516,"primaryCompletion":49,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":521},[89],"2027-12","2022-12-07",261,[24],[50],{"nctId":523,"briefTitle":524,"status":137,"phases":525,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT04397562","A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",[89],"2020-07-03","2020-08-03","2020-04-29",206,[531],"COVID-19",[50],{"trials":534,"activeCount":12},[],{"trials":536,"activeCount":12},[],{"intervention":79,"totalTrials":144,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":554,"PHASE3":556,"PHASE4":565,"NA":567},{"trials":540,"activeCount":12},[],{"trials":542,"activeCount":12},[543],{"nctId":544,"briefTitle":545,"status":160,"phases":546,"primaryCompletion":547,"completion":39,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT05738993","A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers",[87],"2023-04-30","2022-08-08",100,[551],"Breast Cancer",[79,553],"Perjeta",{"trials":555,"activeCount":12},[],{"trials":557,"activeCount":112,"soonestReadout":78},[558],{"nctId":76,"briefTitle":77,"status":118,"phases":559,"primaryCompletion":78,"completion":560,"start":561,"enrollment":562,"conditions":563,"interventions":564},[89],"2026-02-20","2023-01-30",398,[551],[79,553],{"trials":566,"activeCount":12},[],{"trials":568,"activeCount":12},[],{"intervention":553,"totalTrials":144,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":579,"PHASE3":581,"PHASE4":587,"NA":589},{"trials":572,"activeCount":12},[],{"trials":574,"activeCount":12},[575],{"nctId":544,"briefTitle":545,"status":160,"phases":576,"primaryCompletion":547,"completion":39,"start":548,"enrollment":549,"conditions":577,"interventions":578},[87],[551],[79,553],{"trials":580,"activeCount":12},[],{"trials":582,"activeCount":112,"soonestReadout":78},[583],{"nctId":76,"briefTitle":77,"status":118,"phases":584,"primaryCompletion":78,"completion":560,"start":561,"enrollment":562,"conditions":585,"interventions":586},[89],[551],[79,553],{"trials":588,"activeCount":12},[],{"trials":590,"activeCount":12},[],{"intervention":183,"totalTrials":112,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":605,"NA":607},{"trials":594,"activeCount":12},[],{"trials":596,"activeCount":12},[],{"trials":598,"activeCount":12},[],{"trials":600,"activeCount":112,"soonestReadout":176},[601],{"nctId":173,"briefTitle":174,"status":118,"phases":602,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":603,"interventions":604},[89],[181,29],[45,183],{"trials":606,"activeCount":12},[],{"trials":608,"activeCount":12},[],{"intervention":60,"totalTrials":112,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":627,"NA":629},{"trials":612,"activeCount":12},[],{"trials":614,"activeCount":12},[],{"trials":616,"activeCount":12},[],{"trials":618,"activeCount":112,"soonestReadout":59},[619],{"nctId":57,"briefTitle":58,"status":118,"phases":620,"primaryCompletion":59,"completion":494,"start":621,"enrollment":622,"conditions":623,"interventions":625},[89],"2023-12-25",421,[624],"Axial Spondyloarthritis",[60,626],"Adalimumab subcutaneous",{"trials":628,"activeCount":12},[],{"trials":630,"activeCount":12},[],{"intervention":626,"totalTrials":112,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":645,"NA":647},{"trials":634,"activeCount":12},[],{"trials":636,"activeCount":12},[],{"trials":638,"activeCount":12},[],{"trials":640,"activeCount":112,"soonestReadout":59},[641],{"nctId":57,"briefTitle":58,"status":118,"phases":642,"primaryCompletion":59,"completion":494,"start":621,"enrollment":622,"conditions":643,"interventions":644},[89],[624],[60,626],{"trials":646,"activeCount":12},[],{"trials":648,"activeCount":12},[],{"intervention":650,"totalTrials":112,"cells":651},"ANB-002",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":671,"NA":673},{"trials":653,"activeCount":12},[],{"trials":655,"activeCount":12},[],{"trials":657,"activeCount":12},[],{"trials":659,"activeCount":112,"soonestReadout":664},[660],{"nctId":661,"briefTitle":662,"status":102,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":670},"NCT06700096","An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B",[89],"2027-04","2032-03","2024-11-07",24,[669],"Hemophilia B",[650],{"trials":672,"activeCount":12},[],{"trials":674,"activeCount":12},[],{"intervention":676,"totalTrials":112,"cells":677},"BCD-281",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":696,"NA":698},{"trials":679,"activeCount":12},[],{"trials":681,"activeCount":12},[],{"trials":683,"activeCount":12},[],{"trials":685,"activeCount":112,"soonestReadout":690},[686],{"nctId":687,"briefTitle":688,"status":102,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":308,"conditions":692,"interventions":694},"NCT07321093","A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis",[89],"2028-12","2025-11-01",[693],"Relapsing-remitting Multiple Sclerosis (RRMS)",[676,695],"Ocrelizumab",{"trials":697,"activeCount":12},[],{"trials":699,"activeCount":12},[],{"intervention":695,"totalTrials":112,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":714,"NA":716},{"trials":703,"activeCount":12},[],{"trials":705,"activeCount":12},[],{"trials":707,"activeCount":12},[],{"trials":709,"activeCount":112,"soonestReadout":690},[710],{"nctId":687,"briefTitle":688,"status":102,"phases":711,"primaryCompletion":690,"completion":690,"start":691,"enrollment":308,"conditions":712,"interventions":713},[89],[693],[676,695],{"trials":715,"activeCount":12},[],{"trials":717,"activeCount":12},[],{"intervention":500,"totalTrials":112,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":732,"NA":734},{"trials":721,"activeCount":12},[],{"trials":723,"activeCount":12},[],{"trials":725,"activeCount":12},[],{"trials":727,"activeCount":112,"soonestReadout":493},[728],{"nctId":490,"briefTitle":491,"status":118,"phases":729,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":730,"interventions":731},[89],[498],[500,470],{"trials":733,"activeCount":12},[],{"trials":735,"activeCount":12},[],{"intervention":737,"totalTrials":144,"cells":738},"anti-TL1A monoclonal antibody, low dose",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":740,"activeCount":12},[],{"trials":742,"activeCount":12},[],{"trials":744,"activeCount":144,"soonestReadout":176},[745,758],{"nctId":746,"briefTitle":747,"status":102,"phases":748,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":755},"NCT07078994","Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease",[88],"2027-05","2029-01","2025-08-14",204,[754],"Crohn's Disease (CD)",[737,756,757],"anti-TL1A monoclonal antibody, medium dose","anti-TL1A monoclonal antibody, high dose",{"nctId":759,"briefTitle":760,"status":102,"phases":761,"primaryCompletion":176,"completion":762,"start":751,"enrollment":763,"conditions":764,"interventions":766},"NCT07080034","Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis",[88],"2028-10",198,[765],"Ulcerative Colitis (UC)",[737,756,757],{"trials":768,"activeCount":12},[],{"trials":770,"activeCount":12},[],{"trials":772,"activeCount":12},[],{"intervention":756,"totalTrials":144,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":776,"activeCount":12},[],{"trials":778,"activeCount":12},[],{"trials":780,"activeCount":144,"soonestReadout":176},[781,785],{"nctId":746,"briefTitle":747,"status":102,"phases":782,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":783,"interventions":784},[88],[754],[737,756,757],{"nctId":759,"briefTitle":760,"status":102,"phases":786,"primaryCompletion":176,"completion":762,"start":751,"enrollment":763,"conditions":787,"interventions":788},[88],[765],[737,756,757],{"trials":790,"activeCount":12},[],{"trials":792,"activeCount":12},[],{"trials":794,"activeCount":12},[],{"intervention":757,"totalTrials":144,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":798,"activeCount":12},[],{"trials":800,"activeCount":12},[],{"trials":802,"activeCount":144,"soonestReadout":176},[803,807],{"nctId":746,"briefTitle":747,"status":102,"phases":804,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":805,"interventions":806},[88],[754],[737,756,757],{"nctId":759,"briefTitle":760,"status":102,"phases":808,"primaryCompletion":176,"completion":762,"start":751,"enrollment":763,"conditions":809,"interventions":810},[88],[765],[737,756,757],{"trials":812,"activeCount":12},[],{"trials":814,"activeCount":12},[],{"trials":816,"activeCount":12},[],{"intervention":818,"totalTrials":112,"cells":819},"anti-TRBV9 monoclonal antibody, low dose",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":821,"activeCount":12},[],{"trials":823,"activeCount":12},[],{"trials":825,"activeCount":112,"soonestReadout":220},[826],{"nctId":827,"briefTitle":828,"status":118,"phases":829,"primaryCompletion":220,"completion":177,"start":830,"enrollment":831,"conditions":832,"interventions":833},"NCT05445076","Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis",[88],"2022-04-19",250,[624],[818,834],"anti-TRBV9 monoclonal antibody, high dose",{"trials":836,"activeCount":12},[],{"trials":838,"activeCount":12},[],{"trials":840,"activeCount":12},[],{"intervention":834,"totalTrials":112,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":853,"PHASE4":855,"NA":857},{"trials":844,"activeCount":12},[],{"trials":846,"activeCount":12},[],{"trials":848,"activeCount":112,"soonestReadout":220},[849],{"nctId":827,"briefTitle":828,"status":118,"phases":850,"primaryCompletion":220,"completion":177,"start":830,"enrollment":831,"conditions":851,"interventions":852},[88],[624],[818,834],{"trials":854,"activeCount":12},[],{"trials":856,"activeCount":12},[],{"trials":858,"activeCount":12},[],{"intervention":860,"totalTrials":112,"cells":861},"ANB-002, dose 1",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":863,"activeCount":12},[],{"trials":865,"activeCount":12},[],{"trials":867,"activeCount":112,"soonestReadout":872},[868],{"nctId":869,"briefTitle":870,"status":102,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":877},"NCT06120582","Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)",[87,88],"2025-11","2029-11","2023-05-02",28,[669],[860,878,879],"ANB-002, dose 2","ANB-002, dose 3",{"trials":881,"activeCount":12},[],{"trials":883,"activeCount":12},[],{"trials":885,"activeCount":12},[],{"intervention":878,"totalTrials":112,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":898,"PHASE4":900,"NA":902},{"trials":889,"activeCount":12},[],{"trials":891,"activeCount":12},[],{"trials":893,"activeCount":112,"soonestReadout":872},[894],{"nctId":869,"briefTitle":870,"status":102,"phases":895,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":896,"interventions":897},[87,88],[669],[860,878,879],{"trials":899,"activeCount":12},[],{"trials":901,"activeCount":12},[],{"trials":903,"activeCount":12},[],{"intervention":879,"totalTrials":112,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":907,"activeCount":12},[],{"trials":909,"activeCount":12},[],{"trials":911,"activeCount":112,"soonestReadout":872},[912],{"nctId":869,"briefTitle":870,"status":102,"phases":913,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":914,"interventions":915},[87,88],[669],[860,878,879],{"trials":917,"activeCount":12},[],{"trials":919,"activeCount":12},[],{"trials":921,"activeCount":12},[],{"intervention":923,"totalTrials":112,"cells":924},"ANB-010, dose 1",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":926,"activeCount":12},[],{"trials":928,"activeCount":12},[],{"trials":930,"activeCount":112,"soonestReadout":220},[931],{"nctId":932,"briefTitle":933,"status":118,"phases":934,"primaryCompletion":220,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":940},"NCT06185335","A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A",[87,88],"2033-06","2023-07-26",50,[939],"Hemophilia A",[923,941,942],"ANB-010, dose 2","ANB-010, dose 3",{"trials":944,"activeCount":12},[],{"trials":946,"activeCount":12},[],{"trials":948,"activeCount":12},[],{"intervention":941,"totalTrials":112,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":952,"activeCount":12},[],{"trials":954,"activeCount":12},[],{"trials":956,"activeCount":112,"soonestReadout":220},[957],{"nctId":932,"briefTitle":933,"status":118,"phases":958,"primaryCompletion":220,"completion":935,"start":936,"enrollment":937,"conditions":959,"interventions":960},[87,88],[939],[923,941,942],{"trials":962,"activeCount":12},[],{"trials":964,"activeCount":12},[],{"trials":966,"activeCount":12},[],{"intervention":942,"totalTrials":112,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":970,"activeCount":12},[],{"trials":972,"activeCount":12},[],{"trials":974,"activeCount":112,"soonestReadout":220},[975],{"nctId":932,"briefTitle":933,"status":118,"phases":976,"primaryCompletion":220,"completion":935,"start":936,"enrollment":937,"conditions":977,"interventions":978},[87,88],[939],[923,941,942],{"trials":980,"activeCount":12},[],{"trials":982,"activeCount":12},[],{"trials":984,"activeCount":12},[],{"intervention":986,"totalTrials":112,"cells":987},"BCD-236",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":989,"activeCount":12},[],{"trials":991,"activeCount":12},[],{"trials":993,"activeCount":112,"soonestReadout":220},[994],{"nctId":995,"briefTitle":996,"status":102,"phases":997,"primaryCompletion":220,"completion":749,"start":998,"enrollment":999,"conditions":1000,"interventions":1002},"NCT07108309","BCD-236 in Combination With Chemotherapy in Patients With Relapsed and\u002For Metastatic Triple Negative Breast Cancer",[88],"2024-07-15",124,[1001],"Triple Negative Breast Cancer",[986,1003],"Chemotherapy",{"trials":1005,"activeCount":12},[],{"trials":1007,"activeCount":12},[],{"trials":1009,"activeCount":12},[],{"intervention":1003,"totalTrials":112,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":12},[],{"trials":1015,"activeCount":12},[],{"trials":1017,"activeCount":112,"soonestReadout":220},[1018],{"nctId":995,"briefTitle":996,"status":102,"phases":1019,"primaryCompletion":220,"completion":749,"start":998,"enrollment":999,"conditions":1020,"interventions":1021},[88],[1001],[986,1003],{"trials":1023,"activeCount":12},[],{"trials":1025,"activeCount":12},[],{"trials":1027,"activeCount":12},[],{"intervention":1029,"totalTrials":112,"cells":1030},"BCD-248",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1032,"activeCount":12},[],{"trials":1034,"activeCount":12},[],{"trials":1036,"activeCount":112,"soonestReadout":1041},[1037],{"nctId":1038,"briefTitle":1039,"status":102,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":549,"conditions":1044,"interventions":1046},"NCT06668792","An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed\u002FRefractory Multiple Myeloma",[88],"2026-02","2028-07","2024-12-26",[1045],"Relapsed\u002FRefractory Multiple Myeloma",[1029],{"trials":1048,"activeCount":12},[],{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":12},[],{"intervention":84,"totalTrials":112,"cells":1054},{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1056,"activeCount":12},[],{"trials":1058,"activeCount":12},[],{"trials":1060,"activeCount":112,"soonestReadout":83},[1061],{"nctId":81,"briefTitle":82,"status":102,"phases":1062,"primaryCompletion":83,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1068},[87,88],"2030-08","2023-02-02",40,[1067],"Spinal Muscular Atrophy (SMA)",[84,1069,1070],"ANB-004, dose 2","ANB-004, dose 3",{"trials":1072,"activeCount":12},[],{"trials":1074,"activeCount":12},[],{"trials":1076,"activeCount":12},[],{"intervention":1069,"totalTrials":112,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":12},[],{"trials":1082,"activeCount":12},[],{"trials":1084,"activeCount":112,"soonestReadout":83},[1085],{"nctId":81,"briefTitle":82,"status":102,"phases":1086,"primaryCompletion":83,"completion":1063,"start":1064,"enrollment":1065,"conditions":1087,"interventions":1088},[87,88],[1067],[84,1069,1070],{"trials":1090,"activeCount":12},[],{"trials":1092,"activeCount":12},[],{"trials":1094,"activeCount":12},[],{"intervention":1070,"totalTrials":112,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":12},[],{"trials":1100,"activeCount":12},[],{"trials":1102,"activeCount":112,"soonestReadout":83},[1103],{"nctId":81,"briefTitle":82,"status":102,"phases":1104,"primaryCompletion":83,"completion":1063,"start":1064,"enrollment":1065,"conditions":1105,"interventions":1106},[87,88],[1067],[84,1069,1070],{"trials":1108,"activeCount":12},[],{"trials":1110,"activeCount":12},[],{"trials":1112,"activeCount":12},[],{"intervention":111,"totalTrials":112,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1116,"activeCount":12},[],{"trials":1118,"activeCount":112,"soonestReadout":104},[1119],{"nctId":100,"briefTitle":101,"status":102,"phases":1120,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":1121,"interventions":1122},[87],[109],[111,111,111,55,111],{"trials":1124,"activeCount":12},[],{"trials":1126,"activeCount":12},[],{"trials":1128,"activeCount":12},[],{"trials":1130,"activeCount":12},[],{"intervention":74,"totalTrials":112,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1134,"activeCount":12},[],{"trials":1136,"activeCount":112,"soonestReadout":73},[1137],{"nctId":71,"briefTitle":72,"status":102,"phases":1138,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1142},[87],"2024-03-29",48,[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],"BCD-261, dose 2","BCD-261, dose 3","BCD-261, dose 4","BCD-261, dose 5","BCD-261, dose 6","BCD-261, pre-specified therapeautic dose X","BCD-261, pre-specified therapeautic dose Y",{"trials":1151,"activeCount":12},[],{"trials":1153,"activeCount":12},[],{"trials":1155,"activeCount":12},[],{"trials":1157,"activeCount":12},[],{"intervention":1143,"totalTrials":112,"cells":1159},{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1161,"activeCount":12},[],{"trials":1163,"activeCount":112,"soonestReadout":73},[1164],{"nctId":71,"briefTitle":72,"status":102,"phases":1165,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1166,"interventions":1167},[87],[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],{"trials":1169,"activeCount":12},[],{"trials":1171,"activeCount":12},[],{"trials":1173,"activeCount":12},[],{"trials":1175,"activeCount":12},[],{"intervention":1144,"totalTrials":112,"cells":1177},{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1179,"activeCount":12},[],{"trials":1181,"activeCount":112,"soonestReadout":73},[1182],{"nctId":71,"briefTitle":72,"status":102,"phases":1183,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1184,"interventions":1185},[87],[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],{"trials":1187,"activeCount":12},[],{"trials":1189,"activeCount":12},[],{"trials":1191,"activeCount":12},[],{"trials":1193,"activeCount":12},[],{"intervention":1145,"totalTrials":112,"cells":1195},{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1204,"PHASE3":1206,"PHASE4":1208,"NA":1210},{"trials":1197,"activeCount":12},[],{"trials":1199,"activeCount":112,"soonestReadout":73},[1200],{"nctId":71,"briefTitle":72,"status":102,"phases":1201,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1202,"interventions":1203},[87],[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],{"trials":1205,"activeCount":12},[],{"trials":1207,"activeCount":12},[],{"trials":1209,"activeCount":12},[],{"trials":1211,"activeCount":12},[],{"intervention":1146,"totalTrials":112,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1222,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1215,"activeCount":12},[],{"trials":1217,"activeCount":112,"soonestReadout":73},[1218],{"nctId":71,"briefTitle":72,"status":102,"phases":1219,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1220,"interventions":1221},[87],[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],{"trials":1223,"activeCount":12},[],{"trials":1225,"activeCount":12},[],{"trials":1227,"activeCount":12},[],{"trials":1229,"activeCount":12},[],{"intervention":1147,"totalTrials":112,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1240,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1233,"activeCount":12},[],{"trials":1235,"activeCount":112,"soonestReadout":73},[1236],{"nctId":71,"briefTitle":72,"status":102,"phases":1237,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1238,"interventions":1239},[87],[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],{"trials":1241,"activeCount":12},[],{"trials":1243,"activeCount":12},[],{"trials":1245,"activeCount":12},[],{"trials":1247,"activeCount":12},[],{"intervention":1148,"totalTrials":112,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1258,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1251,"activeCount":12},[],{"trials":1253,"activeCount":112,"soonestReadout":73},[1254],{"nctId":71,"briefTitle":72,"status":102,"phases":1255,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1256,"interventions":1257},[87],[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],{"trials":1259,"activeCount":12},[],{"trials":1261,"activeCount":12},[],{"trials":1263,"activeCount":12},[],{"trials":1265,"activeCount":12},[],{"intervention":1149,"totalTrials":112,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1276,"PHASE3":1278,"PHASE4":1280,"NA":1282},{"trials":1269,"activeCount":12},[],{"trials":1271,"activeCount":112,"soonestReadout":73},[1272],{"nctId":71,"briefTitle":72,"status":102,"phases":1273,"primaryCompletion":73,"completion":220,"start":1139,"enrollment":1140,"conditions":1274,"interventions":1275},[87],[15],[74,1143,1144,1145,1146,1147,1148,1148,1149],{"trials":1277,"activeCount":12},[],{"trials":1279,"activeCount":12},[],{"trials":1281,"activeCount":12},[],{"trials":1283,"activeCount":12},[],{"intervention":1285,"totalTrials":112,"cells":1286},"Adalimumab (BCD-057) 100 mg\u002FmL",{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1288,"activeCount":12},[],{"trials":1290,"activeCount":112,"soonestReadout":872},[1291],{"nctId":1292,"briefTitle":1293,"status":102,"phases":1294,"primaryCompletion":872,"completion":872,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1299},"NCT07181694","A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg\u002FmL, BCD-057 50 mg\u002FmL, and Humira 100 mg\u002FmL in Healthy Subjects",[87],"2025-03-12",444,[1298],"Healthy Adult Male",[1285,1300,1301],"Adalimumab (BCD-057) 50 mg\u002FmL","Adalimumab (Humira) 100 mg\u002FmL",{"trials":1303,"activeCount":12},[],{"trials":1305,"activeCount":12},[],{"trials":1307,"activeCount":12},[],{"trials":1309,"activeCount":12},[],{"intervention":1300,"totalTrials":112,"cells":1311},{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1313,"activeCount":12},[],{"trials":1315,"activeCount":112,"soonestReadout":872},[1316],{"nctId":1292,"briefTitle":1293,"status":102,"phases":1317,"primaryCompletion":872,"completion":872,"start":1295,"enrollment":1296,"conditions":1318,"interventions":1319},[87],[1298],[1285,1300,1301],{"trials":1321,"activeCount":12},[],{"trials":1323,"activeCount":12},[],{"trials":1325,"activeCount":12},[],{"trials":1327,"activeCount":12},[],{"intervention":1301,"totalTrials":112,"cells":1329},{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1331,"activeCount":12},[],{"trials":1333,"activeCount":112,"soonestReadout":872},[1334],{"nctId":1292,"briefTitle":1293,"status":102,"phases":1335,"primaryCompletion":872,"completion":872,"start":1295,"enrollment":1296,"conditions":1336,"interventions":1337},[87],[1298],[1285,1300,1301],{"trials":1339,"activeCount":12},[],{"trials":1341,"activeCount":12},[],{"trials":1343,"activeCount":12},[],{"trials":1345,"activeCount":12},[],{"intervention":1347,"totalTrials":22,"cells":1348},"BCD-085",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1384,"PHASE4":1406,"NA":1408},{"trials":1350,"activeCount":12},[],{"trials":1352,"activeCount":12},[],{"trials":1354,"activeCount":12},[1355,1364,1374],{"nctId":1356,"briefTitle":1357,"status":137,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1363},"NCT02763111","Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis",[88],"2017-06","2016-09",88,[26],[1347],{"nctId":1365,"briefTitle":1366,"status":1367,"phases":1368,"primaryCompletion":164,"completion":164,"start":1369,"enrollment":1370,"conditions":1371,"interventions":1373},"NCT03476993","Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis","TERMINATED",[88],"2018-04-27",9,[1372],"Liver Cirrhosis, Biliary",[1347],{"nctId":1375,"briefTitle":1376,"status":137,"phases":1377,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1383},"NCT02762994","International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis",[88],"2017-05","2016-06",120,[1382],"Psoriasis",[1347],{"trials":1385,"activeCount":12},[1386,1397],{"nctId":1387,"briefTitle":1388,"status":137,"phases":1389,"primaryCompletion":1390,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT03598751","Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis",[89],"2019-06-26","2022-08-31","2018-07-25",194,[1395],"Psoriatic Arthritis",[1347],{"nctId":1398,"briefTitle":1399,"status":137,"phases":1400,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":383,"conditions":1404,"interventions":1405},"NCT03447704","International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis",[89],"2018-12-24","2022-03-31","2018-02-09",[26],[1347],{"trials":1407,"activeCount":12},[],{"trials":1409,"activeCount":12},[],{"intervention":288,"totalTrials":22,"cells":1411},{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1425,"PHASE3":1431,"PHASE4":1456,"NA":1458},{"trials":1413,"activeCount":12},[],{"trials":1415,"activeCount":12},[1416],{"nctId":1417,"briefTitle":1418,"status":1419,"phases":1420,"primaryCompletion":1421,"enrollment":12,"conditions":1422,"interventions":1424},"NCT02450981","Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration","WITHDRAWN",[87],"2016-03",[1423],"Neovascular Age-related Macular Degeneration",[288],{"trials":1426,"activeCount":12},[1427],{"nctId":278,"briefTitle":279,"status":160,"phases":1428,"primaryCompletion":281,"completion":281,"start":282,"enrollment":11,"conditions":1429,"interventions":1430},[88],[284,285,286],[169,288,289,290],{"trials":1432,"activeCount":12},[1433,1437,1448],{"nctId":314,"briefTitle":315,"status":160,"phases":1434,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1435,"interventions":1436},[89],[284],[169,288,289,290],{"nctId":1438,"briefTitle":1439,"status":137,"phases":1440,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":1443,"conditions":1444,"interventions":1446},"NCT01763645","A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer",[89],"2014-11","2012-10",353,[1445],"Non-small Cell Lung Cancer",[288,289,1447],"Carboplatin",{"nctId":1449,"briefTitle":1450,"status":1419,"phases":1451,"primaryCompletion":1421,"enrollment":12,"conditions":1452,"interventions":1454},"NCT02036723","Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration",[89],[1453],"Wet Age-related Macular Degeneration",[288,1455],"Ranibizumab",{"trials":1457,"activeCount":12},[],{"trials":1459,"activeCount":12},[],{"intervention":289,"totalTrials":27,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1472,"PHASE4":1493,"NA":1495},{"trials":1463,"activeCount":12},[],{"trials":1465,"activeCount":12},[],{"trials":1467,"activeCount":12},[1468],{"nctId":278,"briefTitle":279,"status":160,"phases":1469,"primaryCompletion":281,"completion":281,"start":282,"enrollment":11,"conditions":1470,"interventions":1471},[88],[284,285,286],[169,288,289,290],{"trials":1473,"activeCount":12},[1474,1485,1489],{"nctId":1475,"briefTitle":1476,"status":137,"phases":1477,"primaryCompletion":1478,"completion":1479,"start":1442,"enrollment":1480,"conditions":1481,"interventions":1483},"NCT01764022","A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients",[89],"2015-03","2017-12",225,[1482],"Human Epithelial Receptor (HER)-2 Positive Breast Cancer",[1484,289],"Trastuzumab",{"nctId":314,"briefTitle":315,"status":160,"phases":1486,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1487,"interventions":1488},[89],[284],[169,288,289,290],{"nctId":1438,"briefTitle":1439,"status":137,"phases":1490,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":1443,"conditions":1491,"interventions":1492},[89],[1445],[288,289,1447],{"trials":1494,"activeCount":12},[],{"trials":1496,"activeCount":12},[],{"intervention":1498,"totalTrials":32,"cells":1499},"Algeron",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1540,"NA":1542},{"trials":1501,"activeCount":12},[],{"trials":1503,"activeCount":12},[],{"trials":1505,"activeCount":12},[],{"trials":1507,"activeCount":12},[1508,1519,1531],{"nctId":1509,"briefTitle":1510,"status":137,"phases":1511,"primaryCompletion":1512,"completion":1512,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1517},"NCT01889433","An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C",[89],"2015-12-02","2013-07-10",170,[34,1516],"Hepatitis C",[1498,1518],"Pegasys",{"nctId":1520,"briefTitle":1521,"status":137,"phases":1522,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1528},"NCT01740089","Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C",[88,89],"2012-07","2013-12","2011-11",150,[34,1516],[1498,1529,1530],"PegIntron","Ribavirin",{"nctId":1532,"briefTitle":1533,"status":137,"phases":1534,"primaryCompletion":1535,"completion":1535,"start":1536,"enrollment":496,"conditions":1537,"interventions":1539},"NCT02103439","An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients",[89],"2015-08-26","2013-06-06",[34,1516,1538],"Hepatitis C\u002F Human Immunodeficiency Virus Coinfection",[1498,1529],{"trials":1541,"activeCount":12},[],{"trials":1543,"activeCount":12},[],{"intervention":290,"totalTrials":32,"cells":1545},{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1556,"PHASE4":1566,"NA":1568},{"trials":1547,"activeCount":12},[],{"trials":1549,"activeCount":12},[],{"trials":1551,"activeCount":12},[1552],{"nctId":278,"briefTitle":279,"status":160,"phases":1553,"primaryCompletion":281,"completion":281,"start":282,"enrollment":11,"conditions":1554,"interventions":1555},[88],[284,285,286],[169,288,289,290],{"trials":1557,"activeCount":12},[1558,1562],{"nctId":304,"briefTitle":305,"status":160,"phases":1559,"primaryCompletion":163,"completion":163,"start":307,"enrollment":308,"conditions":1560,"interventions":1561},[89],[310],[169,312,290],{"nctId":314,"briefTitle":315,"status":160,"phases":1563,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1564,"interventions":1565},[89],[284],[169,288,289,290],{"trials":1567,"activeCount":12},[],{"trials":1569,"activeCount":12},[],{"intervention":1571,"totalTrials":144,"cells":1572},"BCD-132",{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1586,"PHASE3":1588,"PHASE4":1601,"NA":1603},{"trials":1574,"activeCount":12},[],{"trials":1576,"activeCount":12},[1577],{"nctId":1578,"briefTitle":1579,"status":137,"phases":1580,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":667,"conditions":1584,"interventions":1585},"NCT03551275","Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis",[87],"2018-10-18","2019-03-28","2018-02-22",[21],[1571],{"trials":1587,"activeCount":12},[],{"trials":1589,"activeCount":12},[1590],{"nctId":1591,"briefTitle":1592,"status":137,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT05385744","An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis",[89],"2022-09-09","2023-09-29","2021-04-05",336,[21],[1571,1600],"Teriflunomide",{"trials":1602,"activeCount":12},[],{"trials":1604,"activeCount":12},[],{"intervention":1600,"totalTrials":144,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1625,"PHASE4":1631,"NA":1633},{"trials":1608,"activeCount":12},[],{"trials":1610,"activeCount":12},[],{"trials":1612,"activeCount":12},[1613],{"nctId":1614,"briefTitle":1615,"status":137,"phases":1616,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1622},"NCT04056897","Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis",[88],"2020-07-13","2022-01-12","2019-06-07",271,[21],[1623,1600,1624],"BCD-132, 125 mg","BCD-132, 500 mg",{"trials":1626,"activeCount":12},[1627],{"nctId":1591,"briefTitle":1592,"status":137,"phases":1628,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1629,"interventions":1630},[89],[21],[1571,1600],{"trials":1632,"activeCount":12},[],{"trials":1634,"activeCount":12},[],{"intervention":1636,"totalTrials":144,"cells":1637},"BCD-089",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1650,"PHASE3":1652,"PHASE4":1665,"NA":1667},{"trials":1639,"activeCount":12},[],{"trials":1641,"activeCount":12},[1642],{"nctId":1643,"briefTitle":1644,"status":137,"phases":1645,"primaryCompletion":1378,"completion":1378,"start":1646,"enrollment":1647,"conditions":1648,"interventions":1649},"NCT03103438","First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy Subjects",[87],"2016-11",19,[15],[1636],{"trials":1651,"activeCount":12},[],{"trials":1653,"activeCount":12},[1654],{"nctId":1655,"briefTitle":1656,"status":137,"phases":1657,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1663},"NCT04227366","Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis",[89],"2021-03-15","2022-03-01","2019-11-19",154,[24],[1636,1664],"Methotrexat",{"trials":1666,"activeCount":12},[],{"trials":1668,"activeCount":12},[],{"intervention":1670,"totalTrials":144,"cells":1671},"filgrastim",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1690,"PHASE4":1704,"NA":1706},{"trials":1673,"activeCount":12},[],{"trials":1675,"activeCount":12},[],{"trials":1677,"activeCount":12},[1678],{"nctId":1679,"briefTitle":1680,"status":137,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1688},"NCT01569087","Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer",[88],"2013-01","2013-02","2012-05",60,[1687],"Chemotherapy-induced Neutropenia",[1689,1670],"empegfilrastim",{"trials":1691,"activeCount":12},[1692],{"nctId":1693,"briefTitle":1694,"status":137,"phases":1695,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":107,"conditions":1699,"interventions":1700},"NCT02104830","Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients",[89],"2014-06","2014-10","2013-09",[1687],[1701,1702,1703],"Empegfilrastim 6 mg","Filgrastim","Empegfilrastim 7.5 mg",{"trials":1705,"activeCount":12},[],{"trials":1707,"activeCount":12},[],{"intervention":1709,"totalTrials":144,"cells":1710},"rituximab",{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1717,"PHASE4":1741,"NA":1743},{"trials":1712,"activeCount":12},[],{"trials":1714,"activeCount":12},[],{"trials":1716,"activeCount":12},[],{"trials":1718,"activeCount":12},[1719,1731],{"nctId":1720,"briefTitle":1721,"status":137,"phases":1722,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1730},"NCT01701232","Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma",[89],"2017-01","2011-09",174,[1727,1728,1729],"Follicular Non-Hodgkin's Lymphoma","Nodal Marginal Zone Lymphoma","Splenic Marginal Zone Lymphoma",[1709],{"nctId":1732,"briefTitle":1733,"status":137,"phases":1734,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":1737,"conditions":1738,"interventions":1739},"NCT01759030","Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis",[89],"2015-07","2012-12",181,[24],[1740],"Rituximab",{"trials":1742,"activeCount":12},[],{"trials":1744,"activeCount":12},[],{"intervention":1746,"totalTrials":144,"cells":1747},"Rebif",{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1762,"PHASE3":1764,"PHASE4":1777,"NA":1779},{"trials":1749,"activeCount":12},[],{"trials":1751,"activeCount":12},[1752],{"nctId":1753,"briefTitle":1754,"status":137,"phases":1755,"primaryCompletion":480,"completion":1756,"start":1757,"enrollment":1685,"conditions":1758,"interventions":1759},"NCT02359877","Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers",[87],"2015-12","2014-07",[15],[1760,1746,1761],"BCD-054","Avonex",{"trials":1763,"activeCount":12},[],{"trials":1765,"activeCount":12},[1766],{"nctId":1767,"briefTitle":1768,"status":137,"phases":1769,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":1773,"conditions":1774,"interventions":1775},"NCT02727907","Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis",[88,89],"2016-11-21","2017-08-11","2015-02-12",163,[21],[1776,1746],"BCD-033",{"trials":1778,"activeCount":12},[],{"trials":1780,"activeCount":12},[],{"intervention":1782,"totalTrials":144,"cells":1783},"Darbepoetin alfa",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1796,"PHASE3":1798,"PHASE4":1811,"NA":1813},{"trials":1785,"activeCount":12},[],{"trials":1787,"activeCount":12},[1788],{"nctId":1789,"briefTitle":1790,"status":137,"phases":1791,"primaryCompletion":1757,"completion":1757,"start":1792,"enrollment":1793,"conditions":1794,"interventions":1795},"NCT02506881","Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers",[87],"2013-03",74,[15],[1782],{"trials":1797,"activeCount":12},[],{"trials":1799,"activeCount":12},[1800],{"nctId":1801,"briefTitle":1802,"status":137,"phases":1803,"primaryCompletion":1804,"completion":1805,"start":1806,"enrollment":1807,"conditions":1808,"interventions":1810},"NCT02506868","Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients",[89],"2017-01-08","2017-12-21","2015-08-08",196,[385,1809,31],"End Stage Renal Failure on Dialysis",[1782],{"trials":1812,"activeCount":12},[],{"trials":1814,"activeCount":12},[],{"intervention":1816,"totalTrials":144,"cells":1817},"BCD-148",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1833,"PHASE3":1835,"PHASE4":1847,"NA":1849},{"trials":1819,"activeCount":12},[],{"trials":1821,"activeCount":12},[1822],{"nctId":1823,"briefTitle":1824,"status":137,"phases":1825,"primaryCompletion":1826,"completion":1826,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1831},"NCT04027803","Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®",[87],"2019-04-07","2018-09-21",78,[1830],"Healthy Subjects",[1816,1832],"Soliris",{"trials":1834,"activeCount":12},[],{"trials":1836,"activeCount":12},[1837],{"nctId":1838,"briefTitle":1839,"status":137,"phases":1840,"primaryCompletion":1841,"completion":1842,"start":1843,"enrollment":875,"conditions":1844,"interventions":1846},"NCT04060264","Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria",[89],"2020-04-27","2020-12-30","2019-04-04",[1845],"Paroxysmal Nocturnal Hemoglobinuria",[1816,1832],{"trials":1848,"activeCount":12},[],{"trials":1850,"activeCount":12},[],{"intervention":1832,"totalTrials":144,"cells":1852},{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1861,"PHASE3":1863,"PHASE4":1869,"NA":1871},{"trials":1854,"activeCount":12},[],{"trials":1856,"activeCount":12},[1857],{"nctId":1823,"briefTitle":1824,"status":137,"phases":1858,"primaryCompletion":1826,"completion":1826,"start":1827,"enrollment":1828,"conditions":1859,"interventions":1860},[87],[1830],[1816,1832],{"trials":1862,"activeCount":12},[],{"trials":1864,"activeCount":12},[1865],{"nctId":1838,"briefTitle":1839,"status":137,"phases":1866,"primaryCompletion":1841,"completion":1842,"start":1843,"enrollment":875,"conditions":1867,"interventions":1868},[89],[1845],[1816,1832],{"trials":1870,"activeCount":12},[],{"trials":1872,"activeCount":12},[],{"intervention":1529,"totalTrials":144,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1881,"PHASE4":1891,"NA":1893},{"trials":1876,"activeCount":12},[],{"trials":1878,"activeCount":12},[],{"trials":1880,"activeCount":12},[],{"trials":1882,"activeCount":12},[1883,1887],{"nctId":1520,"briefTitle":1521,"status":137,"phases":1884,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1885,"interventions":1886},[88,89],[34,1516],[1498,1529,1530],{"nctId":1532,"briefTitle":1533,"status":137,"phases":1888,"primaryCompletion":1535,"completion":1535,"start":1536,"enrollment":496,"conditions":1889,"interventions":1890},[89],[34,1516,1538],[1498,1529],{"trials":1892,"activeCount":12},[],{"trials":1894,"activeCount":12},[],{"intervention":1896,"totalTrials":144,"cells":1897},"BCD-201",{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1914,"PHASE3":1916,"PHASE4":1928,"NA":1930},{"trials":1899,"activeCount":12},[],{"trials":1901,"activeCount":12},[1902],{"nctId":1903,"briefTitle":1904,"status":160,"phases":1905,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":1909,"conditions":1910,"interventions":1912},"NCT05739006","Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies",[87],"2022-06-21","2023-08-31","2021-02-08",131,[18,1911],"Non Small Cell Lung Cancer",[1896,1913],"Keytruda",{"trials":1915,"activeCount":12},[],{"trials":1917,"activeCount":12},[1918],{"nctId":1919,"briefTitle":1920,"status":160,"phases":1921,"primaryCompletion":1922,"completion":1923,"start":1924,"enrollment":1925,"conditions":1926,"interventions":1927},"NCT05986331","Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma",[89],"2023-12-31","2024-12-31","2022-07-18",366,[29],[1896,1913],{"trials":1929,"activeCount":12},[],{"trials":1931,"activeCount":12},[],{"intervention":1913,"totalTrials":144,"cells":1933},{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1942,"PHASE3":1944,"PHASE4":1950,"NA":1952},{"trials":1935,"activeCount":12},[],{"trials":1937,"activeCount":12},[1938],{"nctId":1903,"briefTitle":1904,"status":160,"phases":1939,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":1909,"conditions":1940,"interventions":1941},[87],[18,1911],[1896,1913],{"trials":1943,"activeCount":12},[],{"trials":1945,"activeCount":12},[1946],{"nctId":1919,"briefTitle":1920,"status":160,"phases":1947,"primaryCompletion":1922,"completion":1923,"start":1924,"enrollment":1925,"conditions":1948,"interventions":1949},[89],[29],[1896,1913],{"trials":1951,"activeCount":12},[],{"trials":1953,"activeCount":12},[],{"intervention":1955,"totalTrials":144,"cells":1956},"Methotrexate",{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1988,"NA":1990},{"trials":1958,"activeCount":12},[],{"trials":1960,"activeCount":12},[],{"trials":1962,"activeCount":12},[],{"trials":1964,"activeCount":12},[1965,1976],{"nctId":1966,"briefTitle":1967,"status":137,"phases":1968,"primaryCompletion":1969,"completion":1970,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1974},"NCT02744196","Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC \"BIOCAD\") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis",[89],"2017-02","2017-08","2015-01",159,[24],[1975,1955],"Acellbia",{"nctId":1977,"briefTitle":1978,"status":137,"phases":1979,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":1983,"interventions":1984},"NCT02762838","Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis",[89],"2018-07","2016-01",426,[24],[1985,1986,1955,1987],"BCD-055","Remicade®","Folic acid",{"trials":1989,"activeCount":12},[],{"trials":1991,"activeCount":12},[],{"intervention":1985,"totalTrials":144,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2014,"NA":2016},{"trials":1995,"activeCount":12},[],{"trials":1997,"activeCount":12},[],{"trials":1999,"activeCount":12},[],{"trials":2001,"activeCount":12},[2002,2010],{"nctId":2003,"briefTitle":2004,"status":137,"phases":2005,"primaryCompletion":1378,"completion":2006,"start":1981,"enrollment":2007,"conditions":2008,"interventions":2009},"NCT02762812","Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis",[89],"2017-07",199,[26],[1985,1986],{"nctId":1977,"briefTitle":1978,"status":137,"phases":2011,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2012,"interventions":2013},[89],[24],[1985,1986,1955,1987],{"trials":2015,"activeCount":12},[],{"trials":2017,"activeCount":12},[],{"intervention":1986,"totalTrials":144,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2026,"PHASE4":2036,"NA":2038},{"trials":2021,"activeCount":12},[],{"trials":2023,"activeCount":12},[],{"trials":2025,"activeCount":12},[],{"trials":2027,"activeCount":12},[2028,2032],{"nctId":2003,"briefTitle":2004,"status":137,"phases":2029,"primaryCompletion":1378,"completion":2006,"start":1981,"enrollment":2007,"conditions":2030,"interventions":2031},[89],[26],[1985,1986],{"nctId":1977,"briefTitle":1978,"status":137,"phases":2033,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2034,"interventions":2035},[89],[24],[1985,1986,1955,1987],{"trials":2037,"activeCount":12},[],{"trials":2039,"activeCount":12},[],{"intervention":1484,"totalTrials":112,"cells":2041},{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2048,"PHASE4":2054,"NA":2056},{"trials":2043,"activeCount":12},[],{"trials":2045,"activeCount":12},[],{"trials":2047,"activeCount":12},[],{"trials":2049,"activeCount":12},[2050],{"nctId":1475,"briefTitle":1476,"status":137,"phases":2051,"primaryCompletion":1478,"completion":1479,"start":1442,"enrollment":1480,"conditions":2052,"interventions":2053},[89],[1482],[1484,289],{"trials":2055,"activeCount":12},[],{"trials":2057,"activeCount":12},[],{"intervention":1664,"totalTrials":112,"cells":2059},{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2066,"PHASE4":2072,"NA":2074},{"trials":2061,"activeCount":12},[],{"trials":2063,"activeCount":12},[],{"trials":2065,"activeCount":12},[],{"trials":2067,"activeCount":12},[2068],{"nctId":1655,"briefTitle":1656,"status":137,"phases":2069,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1661,"conditions":2070,"interventions":2071},[89],[24],[1636,1664],{"trials":2073,"activeCount":12},[],{"trials":2075,"activeCount":12},[],{"intervention":2077,"totalTrials":112,"cells":2078},"BCD-063",{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2098,"NA":2100},{"trials":2080,"activeCount":12},[],{"trials":2082,"activeCount":12},[],{"trials":2084,"activeCount":12},[],{"trials":2086,"activeCount":12},[2087],{"nctId":2088,"briefTitle":2089,"status":137,"phases":2090,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":2093,"conditions":2094,"interventions":2096},"NCT02753088","Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis",[89],"2015-11","2013-10",158,[2095],"Relapsing-remitting Multiple Sclerosis",[2077,2097],"Copaxone-Teva",{"trials":2099,"activeCount":12},[],{"trials":2101,"activeCount":12},[],{"intervention":2097,"totalTrials":112,"cells":2103},{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2116,"NA":2118},{"trials":2105,"activeCount":12},[],{"trials":2107,"activeCount":12},[],{"trials":2109,"activeCount":12},[],{"trials":2111,"activeCount":12},[2112],{"nctId":2088,"briefTitle":2089,"status":137,"phases":2113,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":2093,"conditions":2114,"interventions":2115},[89],[2095],[2077,2097],{"trials":2117,"activeCount":12},[],{"trials":2119,"activeCount":12},[],{"intervention":2121,"totalTrials":112,"cells":2122},"BCD-085 Q2W",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2143,"NA":2145},{"trials":2124,"activeCount":12},[],{"trials":2126,"activeCount":12},[],{"trials":2128,"activeCount":12},[],{"trials":2130,"activeCount":12},[2131],{"nctId":2132,"briefTitle":2133,"status":137,"phases":2134,"primaryCompletion":2135,"completion":2136,"start":2137,"enrollment":2138,"conditions":2139,"interventions":2141},"NCT03390101","An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis",[89],"2018-07-30","2022-01-20","2017-12-26",213,[2140],"Moderate to Severe Plaque Psoriasis",[2121,2142],"BCD-085 Q4W",{"trials":2144,"activeCount":12},[],{"trials":2146,"activeCount":12},[],{"intervention":2142,"totalTrials":112,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2155,"PHASE4":2161,"NA":2163},{"trials":2150,"activeCount":12},[],{"trials":2152,"activeCount":12},[],{"trials":2154,"activeCount":12},[],{"trials":2156,"activeCount":12},[2157],{"nctId":2132,"briefTitle":2133,"status":137,"phases":2158,"primaryCompletion":2135,"completion":2136,"start":2137,"enrollment":2138,"conditions":2159,"interventions":2160},[89],[2140],[2121,2142],{"trials":2162,"activeCount":12},[],{"trials":2164,"activeCount":12},[],{"intervention":2166,"totalTrials":112,"cells":2167},"BCD-054 180 mcg",{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2172,"PHASE3":2174,"PHASE4":2189,"NA":2191},{"trials":2169,"activeCount":12},[],{"trials":2171,"activeCount":12},[],{"trials":2173,"activeCount":12},[],{"trials":2175,"activeCount":12},[2176],{"nctId":2177,"briefTitle":2178,"status":137,"phases":2179,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2186},"NCT02744222","Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis",[88,89],"2018-11-23","2020-07-06","2017-08-10",399,[2185],"Multiple Sclerosis, Relapsing-Remitting",[2166,2187,2188],"Avonex®","BCD-054 240 mcg",{"trials":2190,"activeCount":12},[],{"trials":2192,"activeCount":12},[],{"intervention":2187,"totalTrials":112,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2201,"PHASE4":2207,"NA":2209},{"trials":2196,"activeCount":12},[],{"trials":2198,"activeCount":12},[],{"trials":2200,"activeCount":12},[],{"trials":2202,"activeCount":12},[2203],{"nctId":2177,"briefTitle":2178,"status":137,"phases":2204,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":2183,"conditions":2205,"interventions":2206},[88,89],[2185],[2166,2187,2188],{"trials":2208,"activeCount":12},[],{"trials":2210,"activeCount":12},[],{"intervention":2188,"totalTrials":112,"cells":2212},{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2225,"NA":2227},{"trials":2214,"activeCount":12},[],{"trials":2216,"activeCount":12},[],{"trials":2218,"activeCount":12},[],{"trials":2220,"activeCount":12},[2221],{"nctId":2177,"briefTitle":2178,"status":137,"phases":2222,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":2183,"conditions":2223,"interventions":2224},[88,89],[2185],[2166,2187,2188],{"trials":2226,"activeCount":12},[],{"trials":2228,"activeCount":12},[],{"intervention":2230,"totalTrials":112,"cells":2231},"Prolgolimab",{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2236,"PHASE3":2238,"PHASE4":2250,"NA":2252},{"trials":2233,"activeCount":12},[],{"trials":2235,"activeCount":12},[],{"trials":2237,"activeCount":12},[],{"trials":2239,"activeCount":12},[2240],{"nctId":2241,"briefTitle":2242,"status":160,"phases":2243,"primaryCompletion":2244,"completion":2244,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT05783882","Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma",[89],"2023-06","2022-02-01",114,[2248],"Unresectable or Metastatic Melanoma",[2230],{"trials":2251,"activeCount":12},[],{"trials":2253,"activeCount":12},[],{"intervention":1518,"totalTrials":112,"cells":2255},{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2262,"PHASE4":2268,"NA":2270},{"trials":2257,"activeCount":12},[],{"trials":2259,"activeCount":12},[],{"trials":2261,"activeCount":12},[],{"trials":2263,"activeCount":12},[2264],{"nctId":1509,"briefTitle":1510,"status":137,"phases":2265,"primaryCompletion":1512,"completion":1512,"start":1513,"enrollment":1514,"conditions":2266,"interventions":2267},[89],[34,1516],[1498,1518],{"trials":2269,"activeCount":12},[],{"trials":2271,"activeCount":12},[],{"intervention":1530,"totalTrials":112,"cells":2273},{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2280,"PHASE4":2286,"NA":2288},{"trials":2275,"activeCount":12},[],{"trials":2277,"activeCount":12},[],{"trials":2279,"activeCount":12},[],{"trials":2281,"activeCount":12},[2282],{"nctId":1520,"briefTitle":1521,"status":137,"phases":2283,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":2284,"interventions":2285},[88,89],[34,1516],[1498,1529,1530],{"trials":2287,"activeCount":12},[],{"trials":2289,"activeCount":12},[],{"intervention":312,"totalTrials":112,"cells":2291},{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2298,"PHASE4":2304,"NA":2306},{"trials":2293,"activeCount":12},[],{"trials":2295,"activeCount":12},[],{"trials":2297,"activeCount":12},[],{"trials":2299,"activeCount":12},[2300],{"nctId":304,"briefTitle":305,"status":160,"phases":2301,"primaryCompletion":163,"completion":163,"start":307,"enrollment":308,"conditions":2302,"interventions":2303},[89],[310],[169,312,290],{"trials":2305,"activeCount":12},[],{"trials":2307,"activeCount":12},[],{"intervention":334,"totalTrials":112,"cells":2309},{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2314,"PHASE3":2316,"PHASE4":2322,"NA":2324},{"trials":2311,"activeCount":12},[],{"trials":2313,"activeCount":12},[],{"trials":2315,"activeCount":12},[],{"trials":2317,"activeCount":12},[2318],{"nctId":323,"briefTitle":324,"status":160,"phases":2319,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":2320,"interventions":2321},[88,89],[331,332],[169,334],{"trials":2323,"activeCount":12},[],{"trials":2325,"activeCount":12},[],{"intervention":2327,"totalTrials":112,"cells":2328},"BCD-057",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2347,"NA":2349},{"trials":2330,"activeCount":12},[],{"trials":2332,"activeCount":12},[],{"trials":2334,"activeCount":12},[],{"trials":2336,"activeCount":12},[2337],{"nctId":2338,"briefTitle":2339,"status":137,"phases":2340,"primaryCompletion":1479,"completion":2341,"start":2342,"enrollment":2343,"conditions":2344,"interventions":2345},"NCT02762955","Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis",[89],"2018-10-15","2016-12",344,[1382],[2327,2346],"Humira®",{"trials":2348,"activeCount":12},[],{"trials":2350,"activeCount":12},[],{"intervention":2346,"totalTrials":112,"cells":2352},{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2365,"NA":2367},{"trials":2354,"activeCount":12},[],{"trials":2356,"activeCount":12},[],{"trials":2358,"activeCount":12},[],{"trials":2360,"activeCount":12},[2361],{"nctId":2338,"briefTitle":2339,"status":137,"phases":2362,"primaryCompletion":1479,"completion":2341,"start":2342,"enrollment":2343,"conditions":2363,"interventions":2364},[89],[1382],[2327,2346],{"trials":2366,"activeCount":12},[],{"trials":2368,"activeCount":12},[],{"intervention":1701,"totalTrials":112,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2383,"NA":2385},{"trials":2372,"activeCount":12},[],{"trials":2374,"activeCount":12},[],{"trials":2376,"activeCount":12},[],{"trials":2378,"activeCount":12},[2379],{"nctId":1693,"briefTitle":1694,"status":137,"phases":2380,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":107,"conditions":2381,"interventions":2382},[89],[1687],[1701,1702,1703],{"trials":2384,"activeCount":12},[],{"trials":2386,"activeCount":12},[],{"intervention":1703,"totalTrials":112,"cells":2388},{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2395,"PHASE4":2401,"NA":2403},{"trials":2390,"activeCount":12},[],{"trials":2392,"activeCount":12},[],{"trials":2394,"activeCount":12},[],{"trials":2396,"activeCount":12},[2397],{"nctId":1693,"briefTitle":1694,"status":137,"phases":2398,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":107,"conditions":2399,"interventions":2400},[89],[1687],[1701,1702,1703],{"trials":2402,"activeCount":12},[],{"trials":2404,"activeCount":12},[],{"intervention":1447,"totalTrials":112,"cells":2406},{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2411,"PHASE3":2413,"PHASE4":2419,"NA":2421},{"trials":2408,"activeCount":12},[],{"trials":2410,"activeCount":12},[],{"trials":2412,"activeCount":12},[],{"trials":2414,"activeCount":12},[2415],{"nctId":1438,"briefTitle":1439,"status":137,"phases":2416,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":1443,"conditions":2417,"interventions":2418},[89],[1445],[288,289,1447],{"trials":2420,"activeCount":12},[],{"trials":2422,"activeCount":12},[],{"intervention":1975,"totalTrials":112,"cells":2424},{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2437,"NA":2439},{"trials":2426,"activeCount":12},[],{"trials":2428,"activeCount":12},[],{"trials":2430,"activeCount":12},[],{"trials":2432,"activeCount":12},[2433],{"nctId":1966,"briefTitle":1967,"status":137,"phases":2434,"primaryCompletion":1969,"completion":1970,"start":1971,"enrollment":1972,"conditions":2435,"interventions":2436},[89],[24],[1975,1955],{"trials":2438,"activeCount":12},[],{"trials":2440,"activeCount":12},[],{"intervention":2442,"totalTrials":112,"cells":2443},"eculizumab",{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2450,"PHASE4":2461,"NA":2463},{"trials":2445,"activeCount":12},[],{"trials":2447,"activeCount":12},[],{"trials":2449,"activeCount":12},[],{"trials":2451,"activeCount":12},[2452],{"nctId":2453,"briefTitle":2454,"status":137,"phases":2455,"primaryCompletion":2456,"completion":2456,"start":2457,"enrollment":667,"conditions":2458,"interventions":2460},"NCT06987864","An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2\u002FNOCTURN",[89],"2022-11-02","2020-04-13",[2459],"Paroxysmal Nocturnal Hemoglobinuria (PNH)",[2442],{"trials":2462,"activeCount":12},[],{"trials":2464,"activeCount":12},[],{"intervention":2466,"totalTrials":112,"cells":2467},"Sodium Enoxaparine",{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2474,"PHASE4":2483,"NA":2485},{"trials":2469,"activeCount":12},[],{"trials":2471,"activeCount":12},[],{"trials":2473,"activeCount":12},[],{"trials":2475,"activeCount":12},[2476],{"nctId":2477,"briefTitle":2478,"status":137,"phases":2479,"primaryCompletion":1756,"completion":1756,"start":1971,"enrollment":999,"conditions":2480,"interventions":2482},"NCT02368314","A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries",[89],[2481],"Deep Vein Thrombosis",[2466],{"trials":2484,"activeCount":12},[],{"trials":2486,"activeCount":12},[],{"intervention":1776,"totalTrials":112,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2501,"NA":2503},{"trials":2490,"activeCount":12},[],{"trials":2492,"activeCount":12},[],{"trials":2494,"activeCount":12},[],{"trials":2496,"activeCount":12},[2497],{"nctId":1767,"briefTitle":1768,"status":137,"phases":2498,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":1773,"conditions":2499,"interventions":2500},[88,89],[21],[1776,1746],{"trials":2502,"activeCount":12},[],{"trials":2504,"activeCount":12},[],{"intervention":1455,"totalTrials":112,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2513,"PHASE4":2519,"NA":2521},{"trials":2508,"activeCount":12},[],{"trials":2510,"activeCount":12},[],{"trials":2512,"activeCount":12},[],{"trials":2514,"activeCount":12},[2515],{"nctId":1449,"briefTitle":1450,"status":1419,"phases":2516,"primaryCompletion":1421,"enrollment":12,"conditions":2517,"interventions":2518},[89],[1453],[288,1455],{"trials":2520,"activeCount":12},[],{"trials":2522,"activeCount":12},[],{"intervention":1987,"totalTrials":112,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2537,"NA":2539},{"trials":2526,"activeCount":12},[],{"trials":2528,"activeCount":12},[],{"trials":2530,"activeCount":12},[],{"trials":2532,"activeCount":12},[2533],{"nctId":1977,"briefTitle":1978,"status":137,"phases":2534,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2535,"interventions":2536},[89],[24],[1985,1986,1955,1987],{"trials":2538,"activeCount":12},[],{"trials":2540,"activeCount":12},[],{"intervention":2542,"totalTrials":112,"cells":2543},"Low dose BCD-250",{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2548,"PHASE3":2560,"PHASE4":2562,"NA":2564},{"trials":2545,"activeCount":12},[],{"trials":2547,"activeCount":12},[],{"trials":2549,"activeCount":12},[2550],{"nctId":2551,"briefTitle":2552,"status":1367,"phases":2553,"primaryCompletion":2554,"completion":2554,"start":327,"enrollment":937,"conditions":2555,"interventions":2557},"NCT05037188","Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)",[87,88],"2022-04-18",[2556,531],"Coronavirus Infection",[2542,2558,2559],"High dose BCD-250","Low dose or high dose BCD-250",{"trials":2561,"activeCount":12},[],{"trials":2563,"activeCount":12},[],{"trials":2565,"activeCount":12},[],{"intervention":2558,"totalTrials":112,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2578,"PHASE4":2580,"NA":2582},{"trials":2569,"activeCount":12},[],{"trials":2571,"activeCount":12},[],{"trials":2573,"activeCount":12},[2574],{"nctId":2551,"briefTitle":2552,"status":1367,"phases":2575,"primaryCompletion":2554,"completion":2554,"start":327,"enrollment":937,"conditions":2576,"interventions":2577},[87,88],[2556,531],[2542,2558,2559],{"trials":2579,"activeCount":12},[],{"trials":2581,"activeCount":12},[],{"trials":2583,"activeCount":12},[],{"intervention":2559,"totalTrials":112,"cells":2585},{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2596,"PHASE4":2598,"NA":2600},{"trials":2587,"activeCount":12},[],{"trials":2589,"activeCount":12},[],{"trials":2591,"activeCount":12},[2592],{"nctId":2551,"briefTitle":2552,"status":1367,"phases":2593,"primaryCompletion":2554,"completion":2554,"start":327,"enrollment":937,"conditions":2594,"interventions":2595},[87,88],[2556,531],[2542,2558,2559],{"trials":2597,"activeCount":12},[],{"trials":2599,"activeCount":12},[],{"trials":2601,"activeCount":12},[],{"intervention":1689,"totalTrials":112,"cells":2603},{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2605,"activeCount":12},[],{"trials":2607,"activeCount":12},[],{"trials":2609,"activeCount":12},[2610],{"nctId":1679,"briefTitle":1680,"status":137,"phases":2611,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":2612,"interventions":2613},[88],[1687],[1689,1670],{"trials":2615,"activeCount":12},[],{"trials":2617,"activeCount":12},[],{"trials":2619,"activeCount":12},[],{"intervention":1623,"totalTrials":112,"cells":2621},{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2623,"activeCount":12},[],{"trials":2625,"activeCount":12},[],{"trials":2627,"activeCount":12},[2628],{"nctId":1614,"briefTitle":1615,"status":137,"phases":2629,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":1620,"conditions":2630,"interventions":2631},[88],[21],[1623,1600,1624],{"trials":2633,"activeCount":12},[],{"trials":2635,"activeCount":12},[],{"trials":2637,"activeCount":12},[],{"intervention":1624,"totalTrials":112,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2641,"activeCount":12},[],{"trials":2643,"activeCount":12},[],{"trials":2645,"activeCount":12},[2646],{"nctId":1614,"briefTitle":1615,"status":137,"phases":2647,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":1620,"conditions":2648,"interventions":2649},[88],[21],[1623,1600,1624],{"trials":2651,"activeCount":12},[],{"trials":2653,"activeCount":12},[],{"trials":2655,"activeCount":12},[],{"intervention":2657,"totalTrials":112,"cells":2658},"BCD-089, 162 mg, s\u002Fc, qw",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2660,"activeCount":12},[],{"trials":2662,"activeCount":12},[],{"trials":2664,"activeCount":12},[2665],{"nctId":2666,"briefTitle":2667,"status":137,"phases":2668,"primaryCompletion":2669,"completion":2670,"start":2671,"enrollment":122,"conditions":2672,"interventions":2674},"NCT03455842","The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis",[88],"2018-12-31","2019-10-22","2018-02-01",[2673],"Seropositive RA",[2657,2675],"BCD-089, 162 mg, s\u002Fc, q2w",{"trials":2677,"activeCount":12},[],{"trials":2679,"activeCount":12},[],{"trials":2681,"activeCount":12},[],{"intervention":2675,"totalTrials":112,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2685,"activeCount":12},[],{"trials":2687,"activeCount":12},[],{"trials":2689,"activeCount":12},[2690],{"nctId":2666,"briefTitle":2667,"status":137,"phases":2691,"primaryCompletion":2669,"completion":2670,"start":2671,"enrollment":122,"conditions":2692,"interventions":2693},[88],[2673],[2657,2675],{"trials":2695,"activeCount":12},[],{"trials":2697,"activeCount":12},[],{"trials":2699,"activeCount":12},[],{"intervention":2701,"totalTrials":112,"cells":2702},"BCD-135",{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2704,"activeCount":12},[],{"trials":2706,"activeCount":12},[2707],{"nctId":2708,"briefTitle":2709,"status":160,"phases":2710,"primaryCompletion":2711,"completion":2712,"start":2713,"enrollment":2714,"conditions":2715,"interventions":2718},"NCT03464032","A Study of BCD-135 in Patients With Advanced Solid Tumors",[87],"2018-05-31","2018-10-31","2017-10-31",30,[18,2716,269,2717],"NSCLC","Bladder Cancer",[2701],{"trials":2720,"activeCount":12},[],{"trials":2722,"activeCount":12},[],{"trials":2724,"activeCount":12},[],{"trials":2726,"activeCount":12},[],{"intervention":2728,"totalTrials":112,"cells":2729},"BCD-245",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2748},{"trials":2731,"activeCount":12},[],{"trials":2733,"activeCount":12},[2734],{"nctId":2735,"briefTitle":2736,"status":160,"phases":2737,"primaryCompletion":2244,"completion":2244,"start":2738,"enrollment":667,"conditions":2739,"interventions":2741},"NCT05782959","Phase 1 Study of BCD-245 in Subjects With Neuroblastoma",[87],"2021-11-29",[2740],"Neuroblastoma",[2728],{"trials":2743,"activeCount":12},[],{"trials":2745,"activeCount":12},[],{"trials":2747,"activeCount":12},[],{"trials":2749,"activeCount":12},[],{"intervention":1760,"totalTrials":112,"cells":2751},{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2760,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2753,"activeCount":12},[],{"trials":2755,"activeCount":12},[2756],{"nctId":1753,"briefTitle":1754,"status":137,"phases":2757,"primaryCompletion":480,"completion":1756,"start":1757,"enrollment":1685,"conditions":2758,"interventions":2759},[87],[15],[1760,1746,1761],{"trials":2761,"activeCount":12},[],{"trials":2763,"activeCount":12},[],{"trials":2765,"activeCount":12},[],{"trials":2767,"activeCount":12},[],{"intervention":1761,"totalTrials":112,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2771,"activeCount":12},[],{"trials":2773,"activeCount":12},[2774],{"nctId":1753,"briefTitle":1754,"status":137,"phases":2775,"primaryCompletion":480,"completion":1756,"start":1757,"enrollment":1685,"conditions":2776,"interventions":2777},[87],[15],[1760,1746,1761],{"trials":2779,"activeCount":12},[],{"trials":2781,"activeCount":12},[],{"trials":2783,"activeCount":12},[],{"trials":2785,"activeCount":12},[],{"intervention":359,"totalTrials":112,"cells":2787},{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2796,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2789,"activeCount":12},[],{"trials":2791,"activeCount":12},[2792],{"nctId":351,"briefTitle":352,"status":137,"phases":2793,"primaryCompletion":354,"completion":354,"start":355,"enrollment":9,"conditions":2794,"interventions":2795},[87],[357],[344,359,360],{"trials":2797,"activeCount":12},[],{"trials":2799,"activeCount":12},[],{"trials":2801,"activeCount":12},[],{"trials":2803,"activeCount":12},[],{"intervention":360,"totalTrials":112,"cells":2805},{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2814,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2807,"activeCount":12},[],{"trials":2809,"activeCount":12},[2810],{"nctId":351,"briefTitle":352,"status":137,"phases":2811,"primaryCompletion":354,"completion":354,"start":355,"enrollment":9,"conditions":2812,"interventions":2813},[87],[357],[344,359,360],{"trials":2815,"activeCount":12},[],{"trials":2817,"activeCount":12},[],{"trials":2819,"activeCount":12},[],{"trials":2821,"activeCount":12},[],{"intervention":2823,"totalTrials":112,"cells":2824},"Infliximab",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2837,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2826,"activeCount":12},[],{"trials":2828,"activeCount":12},[2829],{"nctId":2830,"briefTitle":2831,"status":137,"phases":2832,"primaryCompletion":2091,"completion":2091,"start":2833,"enrollment":2834,"conditions":2835,"interventions":2836},"NCT02359903","Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis",[87],"2015-02",90,[26],[2823,2823],{"trials":2838,"activeCount":12},[],{"trials":2840,"activeCount":12},[],{"trials":2842,"activeCount":12},[],{"trials":2844,"activeCount":12},[],{"intervention":2846,"totalTrials":112,"cells":2847},"BCD-145",{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2861,"PHASE3":2863,"PHASE4":2865,"NA":2867},{"trials":2849,"activeCount":12},[],{"trials":2851,"activeCount":12},[2852],{"nctId":2853,"briefTitle":2854,"status":137,"phases":2855,"primaryCompletion":2856,"completion":2857,"start":2858,"enrollment":266,"conditions":2859,"interventions":2860},"NCT03472027","Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable\u002FMetastatic Melanoma",[87],"2018-09-11","2018-12-04","2017-10-02",[18],[2846],{"trials":2862,"activeCount":12},[],{"trials":2864,"activeCount":12},[],{"trials":2866,"activeCount":12},[],{"trials":2868,"activeCount":12},[],{"intervention":2870,"totalTrials":112,"cells":2871},"BCD-180, dose 1",{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2891,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2873,"activeCount":12},[],{"trials":2875,"activeCount":12},[2876],{"nctId":2877,"briefTitle":2878,"status":137,"phases":2879,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2883,"interventions":2884},"NCT05407779","Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers",[87],"2023-09-30","2021-01-22",39,[15],[2870,2885,2886,2887,2888,2889,2890],"BCD-180, dose 2","BCD-180, dose 3","BCD-180, dose 4","BCD-180, dose 5","BCD-180, dose 6","BCD-180, dose 7",{"trials":2892,"activeCount":12},[],{"trials":2894,"activeCount":12},[],{"trials":2896,"activeCount":12},[],{"trials":2898,"activeCount":12},[],{"intervention":2885,"totalTrials":112,"cells":2900},{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2909,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2902,"activeCount":12},[],{"trials":2904,"activeCount":12},[2905],{"nctId":2877,"briefTitle":2878,"status":137,"phases":2906,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2907,"interventions":2908},[87],[15],[2870,2885,2886,2887,2888,2889,2890],{"trials":2910,"activeCount":12},[],{"trials":2912,"activeCount":12},[],{"trials":2914,"activeCount":12},[],{"trials":2916,"activeCount":12},[],{"intervention":2886,"totalTrials":112,"cells":2918},{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2927,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2920,"activeCount":12},[],{"trials":2922,"activeCount":12},[2923],{"nctId":2877,"briefTitle":2878,"status":137,"phases":2924,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2925,"interventions":2926},[87],[15],[2870,2885,2886,2887,2888,2889,2890],{"trials":2928,"activeCount":12},[],{"trials":2930,"activeCount":12},[],{"trials":2932,"activeCount":12},[],{"trials":2934,"activeCount":12},[],{"intervention":2887,"totalTrials":112,"cells":2936},{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2945,"PHASE3":2947,"PHASE4":2949,"NA":2951},{"trials":2938,"activeCount":12},[],{"trials":2940,"activeCount":12},[2941],{"nctId":2877,"briefTitle":2878,"status":137,"phases":2942,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2943,"interventions":2944},[87],[15],[2870,2885,2886,2887,2888,2889,2890],{"trials":2946,"activeCount":12},[],{"trials":2948,"activeCount":12},[],{"trials":2950,"activeCount":12},[],{"trials":2952,"activeCount":12},[],{"intervention":2888,"totalTrials":112,"cells":2954},{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2963,"PHASE3":2965,"PHASE4":2967,"NA":2969},{"trials":2956,"activeCount":12},[],{"trials":2958,"activeCount":12},[2959],{"nctId":2877,"briefTitle":2878,"status":137,"phases":2960,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2961,"interventions":2962},[87],[15],[2870,2885,2886,2887,2888,2889,2890],{"trials":2964,"activeCount":12},[],{"trials":2966,"activeCount":12},[],{"trials":2968,"activeCount":12},[],{"trials":2970,"activeCount":12},[],{"intervention":2889,"totalTrials":112,"cells":2972},{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2981,"PHASE3":2983,"PHASE4":2985,"NA":2987},{"trials":2974,"activeCount":12},[],{"trials":2976,"activeCount":12},[2977],{"nctId":2877,"briefTitle":2878,"status":137,"phases":2978,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2979,"interventions":2980},[87],[15],[2870,2885,2886,2887,2888,2889,2890],{"trials":2982,"activeCount":12},[],{"trials":2984,"activeCount":12},[],{"trials":2986,"activeCount":12},[],{"trials":2988,"activeCount":12},[],{"intervention":2890,"totalTrials":112,"cells":2990},{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2999,"PHASE3":3001,"PHASE4":3003,"NA":3005},{"trials":2992,"activeCount":12},[],{"trials":2994,"activeCount":12},[2995],{"nctId":2877,"briefTitle":2878,"status":137,"phases":2996,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2997,"interventions":2998},[87],[15],[2870,2885,2886,2887,2888,2889,2890],{"trials":3000,"activeCount":12},[],{"trials":3002,"activeCount":12},[],{"trials":3004,"activeCount":12},[],{"trials":3006,"activeCount":12},[],{"intervention":3008,"totalTrials":112,"cells":3009},"BCD-147",{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3022,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3011,"activeCount":12},[],{"trials":3013,"activeCount":12},[3014],{"nctId":3015,"briefTitle":3016,"status":137,"phases":3017,"primaryCompletion":3018,"completion":3018,"start":3019,"enrollment":266,"conditions":3020,"interventions":3021},"NCT03912441","First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2\u002FHER2 Antibody) in Healthy Subjects",[87],"2019-09-30","2019-01-30",[15],[3008],{"trials":3023,"activeCount":12},[],{"trials":3025,"activeCount":12},[],{"trials":3027,"activeCount":12},[],{"trials":3029,"activeCount":12},[],{"intervention":3031,"totalTrials":112,"cells":3032},"BCD-121",{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3043,"PHASE3":3045,"PHASE4":3047,"NA":3049},{"trials":3034,"activeCount":12},[],{"trials":3036,"activeCount":12},[3037],{"nctId":3038,"briefTitle":3039,"status":137,"phases":3040,"primaryCompletion":1378,"completion":1378,"start":1646,"enrollment":875,"conditions":3041,"interventions":3042},"NCT03103451","First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects",[87],[15],[3031],{"trials":3044,"activeCount":12},[],{"trials":3046,"activeCount":12},[],{"trials":3048,"activeCount":12},[],{"trials":3050,"activeCount":12},[],{"intervention":3052,"totalTrials":112,"cells":3053},"humanized monoclonal antibody against human IL-17",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3066,"PHASE3":3068,"PHASE4":3070,"NA":3072},{"trials":3055,"activeCount":12},[],{"trials":3057,"activeCount":12},[3058],{"nctId":3059,"briefTitle":3060,"status":137,"phases":3061,"primaryCompletion":3062,"completion":480,"start":1478,"enrollment":3063,"conditions":3064,"interventions":3065},"NCT02380287","First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects",[87],"2015-09",22,[15],[3052],{"trials":3067,"activeCount":12},[],{"trials":3069,"activeCount":12},[],{"trials":3071,"activeCount":12},[],{"trials":3073,"activeCount":12},[],{"intervention":3075,"totalTrials":112,"cells":3076},"BCD-115",{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3089,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3078,"activeCount":12},[],{"trials":3080,"activeCount":12},[3081],{"nctId":3082,"briefTitle":3083,"status":137,"phases":3084,"primaryCompletion":3085,"completion":3085,"start":1646,"enrollment":3086,"conditions":3087,"interventions":3088},"NCT03065010","Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer",[87],"2018-03",6,[551],[3075],{"trials":3090,"activeCount":12},[],{"trials":3092,"activeCount":12},[],{"trials":3094,"activeCount":12},[],{"trials":3096,"activeCount":12},[],{"intervention":3098,"totalTrials":112,"cells":3099},"BCD-066",{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3114,"PHASE3":3116,"PHASE4":3118,"NA":3120},{"trials":3101,"activeCount":12},[],{"trials":3103,"activeCount":12},[3104],{"nctId":3105,"briefTitle":3106,"status":137,"phases":3107,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3111,"interventions":3112},"NCT03693950","The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers",[87],"2017-07-03","2017-03-28",57,[15],[3098,3113],"Aranesp",{"trials":3115,"activeCount":12},[],{"trials":3117,"activeCount":12},[],{"trials":3119,"activeCount":12},[],{"trials":3121,"activeCount":12},[],{"intervention":3113,"totalTrials":112,"cells":3123},{"EARLY_PHASE1":3124,"PHASE1":3126,"PHASE2":3132,"PHASE3":3134,"PHASE4":3136,"NA":3138},{"trials":3125,"activeCount":12},[],{"trials":3127,"activeCount":12},[3128],{"nctId":3105,"briefTitle":3106,"status":137,"phases":3129,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3130,"interventions":3131},[87],[15],[3098,3113],{"trials":3133,"activeCount":12},[],{"trials":3135,"activeCount":12},[],{"trials":3137,"activeCount":12},[],{"trials":3139,"activeCount":12},[],{"intervention":3141,"totalTrials":112,"cells":3142},"Interferon beta-1a",{"EARLY_PHASE1":3143,"PHASE1":3145,"PHASE2":3155,"PHASE3":3157,"PHASE4":3159,"NA":3161},{"trials":3144,"activeCount":12},[],{"trials":3146,"activeCount":12},[3147],{"nctId":3148,"briefTitle":3149,"status":137,"phases":3150,"primaryCompletion":3151,"completion":3151,"start":1683,"enrollment":3152,"conditions":3153,"interventions":3154},"NCT01766024","Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers",[87],"2013-06",32,[15],[3141],{"trials":3156,"activeCount":12},[],{"trials":3158,"activeCount":12},[],{"trials":3160,"activeCount":12},[],{"trials":3162,"activeCount":12},[],{"intervention":3164,"totalTrials":112,"cells":3165},"Leucostim®",{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3180,"PHASE3":3182,"PHASE4":3184,"NA":3186},{"trials":3167,"activeCount":12},[],{"trials":3169,"activeCount":12},[3170],{"nctId":3171,"briefTitle":3172,"status":137,"phases":3173,"primaryCompletion":3174,"completion":3174,"start":3175,"enrollment":1685,"conditions":3176,"interventions":3178},"NCT02762799","Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®",[87],"2016-11-11","2016-07-18",[3177],"Leucocytosis",[3164,3179],"Neupogen®",{"trials":3181,"activeCount":12},[],{"trials":3183,"activeCount":12},[],{"trials":3185,"activeCount":12},[],{"trials":3187,"activeCount":12},[],{"intervention":3179,"totalTrials":112,"cells":3189},{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3198,"PHASE3":3200,"PHASE4":3202,"NA":3204},{"trials":3191,"activeCount":12},[],{"trials":3193,"activeCount":12},[3194],{"nctId":3171,"briefTitle":3172,"status":137,"phases":3195,"primaryCompletion":3174,"completion":3174,"start":3175,"enrollment":1685,"conditions":3196,"interventions":3197},[87],[3177],[3164,3179],{"trials":3199,"activeCount":12},[],{"trials":3201,"activeCount":12},[],{"trials":3203,"activeCount":12},[],{"trials":3205,"activeCount":12},[],{"intervention":3207,"totalTrials":112,"cells":3208},"Empegfilgrastim",{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3210,"activeCount":12},[],{"trials":3212,"activeCount":12},[],{"trials":3214,"activeCount":12},[],{"trials":3216,"activeCount":12},[],{"trials":3218,"activeCount":12},[],{"trials":3220,"activeCount":12},[3221],{"nctId":3222,"briefTitle":3223,"status":160,"phases":3224,"primaryCompletion":3225,"completion":3225,"start":3226,"enrollment":3227,"conditions":3228,"interventions":3230},"NCT04811443","DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs",[],"2022-06-12","2021-01-12",500,[3229],"Patients With Solid Tumours Who Receive Myelosupressive Therapy",[3207]]